Literature DB >> 17680197

Ropivacaine-induced toxicity with overdose suspected after axillary brachial plexus block.

Yoshinobu Kimura1, Yasuhiro Kamada, Akira Kimura, Kaori Orimo.   

Abstract

Ropivacaine has a high threshold for systemic toxicity. We report and highlight a rare case in which an overdose of ropivacaine was suspected of leading to a generalized convulsion following the injection of this agent for axillary brachial plexus block (ABPB). A 25-year-old woman (height, 153 cm; weight, 48 kg; American Society of Anesthesiologists physical status I) was scheduled for finger surgery with ABPB. The perivascular sheath was identified by fascial clicks. We administered 300 mg (6.25 mg x kg(-1)) ropivacaine, while confirming that no blood flow was observed in the injection line by repeated negative aspiration tests. Ten minutes after the injection, most sensory and motor nerves were blocked effectively. Thirteen minutes after the administration, the patient lost consciousness and convulsed suddenly. No severe symptoms of cardiovascular toxicity occurred. The concentration of ropivacaine in a venous blood sample taken 28 min after the ropivacaine injection was 3.65 microg x ml(-1). She recovered with no sequelae. Limited cases have indicated high efficacy and sufficient safety for the use of 300 mg ropivacaine for ABPB. However, the toxic threshold of ropivacaine remains unclear, and the dose should be calculated in relation to the weight of the patient to prevent severe toxic complications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680197     DOI: 10.1007/s00540-007-0518-x

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  23 in total

1.  A multicentre trial of ropivacaine 7.5 mg x ml(-1) vs bupivacaine 5 mg x ml(-1) for supra clavicular brachial plexus anesthesia.

Authors:  H Vaghadia; V Chan; S Ganapathy; A Lui; J McKenna; K Zimmer
Journal:  Can J Anaesth       Date:  1999-10       Impact factor: 5.063

Review 2.  Ropivacaine-induced cardiac arrest after peripheral nerve block: successful resuscitation.

Authors:  Pascal Chazalon; Jean P Tourtier; Thierry Villevielle; Didier Giraud; Jean M Saïssy; Georges Mion; Dan Benhamou
Journal:  Anesthesiology       Date:  2003-12       Impact factor: 7.892

3.  Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers.

Authors:  K Knudsen; M Beckman Suurküla; S Blomberg; J Sjövall; N Edvardsson
Journal:  Br J Anaesth       Date:  1997-05       Impact factor: 9.166

4.  0.75% and 0.5% ropivacaine for axillary brachial plexus block: a clinical comparison with 0.5% bupivacaine.

Authors:  L Bertini; V Tagariello; S Mancini; A Ciaschi; C M Posteraro; P Di Benedetto; O Martini
Journal:  Reg Anesth Pain Med       Date:  1999 Nov-Dec       Impact factor: 6.288

5.  Axillary brachial plexus block with ropivacaine 7.5 mg/ml. A comparative study with bupivacaine 5 mg/ml.

Authors:  J C Raeder; S Drøsdahl; O Klaastad; O Kvalsvik; B Isaksen; K E Strømskag; P Mowinckel; R Bergheim; D Selander
Journal:  Acta Anaesthesiol Scand       Date:  1999-09       Impact factor: 2.105

6.  Acute toxicity of ropivacaine compared with that of bupivacaine.

Authors:  D B Scott; A Lee; D Fagan; G M Bowler; P Bloomfield; R Lundh
Journal:  Anesth Analg       Date:  1989-11       Impact factor: 5.108

7.  Pharmacokinetics and efficacy of 40 ml ropivacaine 7.5 mg/ml (300 mg), for axillary brachial plexus block--an open pilot study.

Authors:  W Wank; J Büttner; K Rissler Maier; B M Emanuelson; D Selander
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

8.  Cardiac arrest after interscalene brachial plexus block with ropivacaine and lidocaine.

Authors:  M Reinikainen; A Hedman; O Pelkonen; E Ruokonen
Journal:  Acta Anaesthesiol Scand       Date:  2003-08       Impact factor: 2.105

9.  Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity.

Authors:  Guy Weinberg; Richard Ripper; Douglas L Feinstein; William Hoffman
Journal:  Reg Anesth Pain Med       Date:  2003 May-Jun       Impact factor: 6.288

10.  Intravenous ropivacaine bolus is a reliable marker of intravascular injection in premedicated healthy volunteers.

Authors:  Colin J L McCartney; Damian B Murphy; Anna Iagounova; Vincent W S Chan
Journal:  Can J Anaesth       Date:  2003-10       Impact factor: 5.063

View more
  10 in total

1.  Midazolam in rabbits terminates dysrhythmias caused by intracerebroventricular ropivacaine.

Authors:  Yao-Min Zhu; Zu-Yi Yuan; Hui Wu; Dan-Dan Zhou; Gui-Xia Jing
Journal:  J Zhejiang Univ Sci B       Date:  2011-08       Impact factor: 3.066

2.  High dose ropivacaine-induced toxicity after infraclavicular block.

Authors:  Chun Woo Yang; Po Soon Kang; Hee Uk Kwon; Dae Jin Lim
Journal:  Korean J Anesthesiol       Date:  2012-01-25

3.  Effects of increasing the dose of ropivacaine on vertical infraclavicular block using neurostimulation.

Authors:  Chun Woo Yang; Po Soon Kang; Hee Uk Kwon; Kyu Chang Lee; Myeong Jong Lee; Hye Young Kim; Eun Kyung Choi; Hyun Kyoung Lim; Chul Woung Kim
Journal:  Korean J Anesthesiol       Date:  2012-07-24

4.  A Comparison of Differences Between the Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion: A Prospective, Randomized, Multicenter, Double-Blind Controlled Trial.

Authors:  Luciano Perotti; Maria Cusato; Pablo Ingelmo; Thekla Larissa Niebel; Marta Somaini; Francesca Riva; Carmine Tinelli; José De Andrés; Guido Fanelli; Antonio Braschi; Mario Regazzi; Massimo Allegri
Journal:  Anesth Analg       Date:  2015-08       Impact factor: 5.108

5.  Inhibition of CD38/Cyclic ADP-ribose Pathway Protects Rats against Ropivacaine-induced Convulsion.

Authors:  Yu Zou; Xin He; Qian-Yi Peng; Qu-Lian Guo
Journal:  Chin Med J (Engl)       Date:  2017-10-05       Impact factor: 2.628

6.  Ropivacaine:An Unusual Cause of Neuroleptic Malignant-Like Syndrome.

Authors:  Miguel Santos; Sheila Arroja; Ana Luisa Antunes; Jose Mariz; Jorge Teixeira
Journal:  Eur J Case Rep Intern Med       Date:  2021-11-08

7.  Local Anesthetic Plasma Concentrations as a Valuable Tool to Confirm the Diagnosis of Local Anesthetic Systemic Toxicity? A Report of 10 Years of Experience.

Authors:  Camille Riff; Axel Le Caloch; Julien Dupouey; Laurent Allanioux; Marc Leone; Olivier Blin; Aurélie Bourgoin; Romain Guilhaumou
Journal:  Pharmaceutics       Date:  2022-03-26       Impact factor: 6.321

8.  Dexmedetomidine pretreatment alleviates ropivacaine-induced neurotoxicity via the miR-10b-5p/BDNF axis.

Authors:  Weicai Xu; Xiaojun Li; Long Chen; Xiaopan Luo; Sheliang Shen; Jing Wang
Journal:  BMC Anesthesiol       Date:  2022-09-26       Impact factor: 2.376

9.  Low-dose ropivacaine for supraclavicular brachial plexus block combined with general anesthesia for successful postoperative analgesia: A case series.

Authors:  Toshio Iwata; Kazuyoshi Nakahashi; Satoki Inoue; Hitoshi Furuya
Journal:  Saudi J Anaesth       Date:  2013-01

10.  Pain relief after ambulatory hand surgery: A comparison between dexmedetomidine and clonidine as adjuvant in axillary brachial plexus block: A prospective, double-blinded, randomized controlled study.

Authors:  A Das; S Dutta; S Chattopadhyay; S Chhaule; T Mitra; R Banu; P Mandal; M Chandra
Journal:  Saudi J Anaesth       Date:  2016 Jan-Mar
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.